Last updated: February 13, 2026
Overview
NDC 16729-0321 corresponds to Tildrakizumab-asmn (Ilumya), a biologic indicated for treatment of moderate-to-severe plaque psoriasis in adult patients. Approved by the FDA in 2018, it belongs to the class of IL-23 inhibitors. Its growth correlates with its positioning as an alternative to other biologics in the psoriasis treatment space.
Market Size and Growth Drivers
Current Market Size
In 2022, the U.S. psoriasis market was valued at approximately USD 3 billion. Tildrakizumab, with a market share of around 10-15%, generates an estimated USD 300-450 million annually in the U.S. alone.
Growth Drivers
- Increasing prevalence of psoriasis: affects roughly 2-3% of the global population, with the U.S. treatment-eligible population estimated at 7 million.
- Expanding indication use: off-label uses for psoriatic arthritis may broaden the potential patient base.
- Competition with other IL-23 and IL-17 inhibitors, such as guselkumab, risankizumab, secukinumab, and ixekizumab.
- Rising adoption of biologics due to their superior efficacy over traditional systemic therapies.
Market Penetration
Market penetration remains moderate, owing to the advent of multiple IL-23 inhibitors. Gaining market share depends on pricing strategies, patient access, and clinician preferences.
Competitive Landscape
| Drug Name |
Mechanism |
Approved Indications |
Market Share (2022) |
List Price (per dose) |
Dosing Schedule |
| Ilumya (Tildrakizumab) |
IL-23 inhibitor |
Psoriasis |
~10-15% |
USD 4,200–4,500 |
100 mg every 12 weeks after initial doses |
| Risankizumab |
IL-23 inhibitor |
Psoriasis, Crohn's |
25-30% |
USD 4,750 |
150 mg every 12 weeks |
| Guselkumab |
IL-23 inhibitor |
Psoriasis |
20-25% |
USD 4,600 |
100 mg every 8 weeks |
Market share shifts toward risankizumab and guselkumab due to perceived efficacy and dosing convenience, impacting Ilumya's sales.
Pricing Trends
List Price Trends
Biologics' list prices remain relatively stable but can vary by payer, region, and discounts:
- In 2022, typical list price for biologic psoriasis agents ranges from USD 4,200 to USD 4,750 per dose.
- Dosing schedules influence annual treatment costs. For Ilumya, with 100 mg doses every 12 weeks, the annual expenditure per patient approximates USD 17,500 based on USD 4,200 per dose.
Pricing Factors
- Payer negotiations provide discounts up to 35-50%, bringing actual net prices lower.
- Biosimilar and follow-on competition are limited in biologics, maintaining high pricing.
Price Projections (2023-2027)
| Year |
Estimated Average Price per Dose |
Annual Cost (per patient) |
Market Penetration Growth |
Notes |
| 2023 |
USD 4,200 |
USD 17,500 |
+5% |
Stable list prices, increasing market share |
| 2024 |
USD 4,150 |
USD 17,200 |
+7% |
Slight decline in price expected due to payer pressure |
| 2025 |
USD 4,100 |
USD 17,000 |
+10% |
Market saturation approaching, competitive pressures increase |
| 2026 |
USD 4,050 |
USD 16,800 |
+8% |
Further pricing compression forecasted |
| 2027 |
USD 4,000 |
USD 16,500 |
+6% |
Price stabilization expected |
Note: Price reductions are driven by payer negotiations, increased competition, and potential biosimilar approvals. The uptake of biosimilars for IL-23 inhibitors is limited, delaying significant price erosion.
Revenue Projections
Annual sales revenue depends on market share and treatment prevalence. Assuming conservative market share growth, the product’s global sales could approximate USD 500-700 million by 2027, factoring in market churning and improved dosing strategies.
Regulatory and Policy Impacts
- Reimbursement policies influence market share dynamics.
- Patent protections provide exclusivity until at least 2030.
- Future biosimilar entry could pressure price reductions post-2025.
Key Takeaways
- NDC 16729-0321 (Ilumya) holds a small but established share of the psoriasis biologics market.
- Pricing remains relatively stable but is vulnerable to payer negotiations and biosimilar development.
- Market growth will mainly stem from increased treatment uptake, driven by psoriasis prevalence and clinician adoption.
- Competition from other IL-23 inhibitors with more convenient dosing schedules and marginally higher efficacy impacts market share.
- Price projections anticipate minor declines by 2027, with steady revenue growth contingent on market penetration.
FAQs
1. What factors influence the pricing of Ilumya?
Pricing is affected by manufacturing costs, payer negotiations, competitive landscape, dosing frequency, and regional policies.
2. How does Ilumya compare to other IL-23 inhibitors?
Ilumya has a lower dosing frequency (every 12 weeks) versus guselkumab (every 8 weeks) and risankizumab (every 12 weeks), which influences clinician preference and market share.
3. When might biosimilars impact Ilumya’s pricing?
Biosimilar competition could emerge from 2025 onwards, potentially reducing prices by 20-40% depending on success and regulatory approvals.
4. What is the expected growth trajectory for Ilumya sales?
Sales are projected to grow modestly (around 5-10% annually), primarily driven by increased patient access and expanding indications.
5. How significant is the patent protection for Ilumya?
Patent protections extend through at least 2030, limiting biosimilar competition during the forecast period.
Sources
- EvaluatePharma. "Biologic Market Share and Pricing Data," 2022.
- FDA. "Ilumya (Tildrakizumab) Approval Documents," 2018.
- IQVIA. "U.S. Biologic Market Analysis," 2022.
- Company filings and press releases, various dates.
- Professional medical and pharmaceutical market reports, 2022-2023.
